![Trigano](/common/images/company/TG_TGO.png)
NEW DELHI, INDIA -- (Marketwire) -- 11/04/09 -- TheFortuneFinancial.com provides the highest level of independent research and investment strategies with the sole purpose of consistently...
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they will complete their merger shortly after 4:00PM ET today. The companies will...
By Peter Loftus Of DOW JONES NEWSWIRES Sales of embattled cholesterol drugs co-marketed by Merck & Co. (MRK) and Schering-Plough Corp. (SGP) could decline further after eagerly awaited...
Interim results of Phase IIa NEXT-I study presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting BOSTON, Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough...
The Food and Drug Administration has turned away a new-drug application which would combine cholesterol treatments Zetia and Lipitor, saying additional data are needed. Lipitor is the world's...
Program Focus: Community Education and Mass Vaccination of Dogs in 10 Villages KENILWORTH, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced it has...
KENILWORTH, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet...
BOSTON, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported two data presentations supporting response guided therapy with boceprevir combination therapy in...
KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corp. (NYSE:SGP) announced today the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.